BMRN
BMRN clinical trials: BIOMARIN PHARMACEUTICAL INC
Every trial on ClinicalTrials.gov where BIOMARIN PHARMACEUTICAL INC is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 171
- Trials linked
- 112
- As lead sponsor
- 59
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BMRN on the catalyst calendar · BMRN registry changes
- Primary completion Sep 16, 2026ActualPhase 2NCT06668805A Study of Vosoritide in Children With Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone TreatmentBioMarin Pharmaceutical · Noonan SyndromeTerminatedBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 23, 2026ActualPhase 3NCT06455059Interventional Study of Vosoritide for the Treatment of Children With HypochondroplasiaBioMarin Pharmaceutical · HypochondroplasiaCompletedBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 4NCT07477691Immune Modulation During Palynziq® Treatment in Adults (IMPALA)BioMarin Pharmaceutical · PhenylketonuriaRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2029Sponsor estimatePhase 2/Phase 3NCT07441876Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With AchondroplasiaBioMarin Pharmaceutical · AchondroplasiaRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 17, 2026ActualPhase 4NCT06780332Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to PalynziqBioMarin Pharmaceutical · PhenylketonuriaCompletedBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2044Sponsor estimatePhase 3NCT07073014Long-Term Extension Study of Vosoritide to Treat Children With HypochondroplasiaBioMarin Pharmaceutical · HypochondroplasiaEnrolling by invitationBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2031Sponsor estimatePhase 2NCT07573631An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular DystrophyBioMarin Pharmaceutical · Duchenne Muscular Dystrophy (DMD)Enrolling by invitationBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2026ActualPhase 1/Phase 2NCT04684940Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior InhibitorsBioMarin Pharmaceutical · Hemophilia A With InhibitorCompletedBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 2028Sponsor estimateNo phase registeredNCT06168201VIrtual STudy in Achondroplasia for the US (VISTA)BioMarin Pharmaceutical · AchondroplasiaRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2030Sponsor estimateNo phase registeredNCT04476862Cerliponase Alfa Observational Study in the USBioMarin Pharmaceutical · Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2Active, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 14, 2027Sponsor estimatePhase 1/Phase 2NCT06280209A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne...BioMarin Pharmaceutical · Duchenne Muscular DystrophyActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 14, 2025ActualPhase 3NCT05270837Study to Evaluate the Safety and Efficacy of Pegvaliase in Adolescents (Ages 12-17) With PhenylketonuriaBioMarin Pharmaceutical · Phenylketonuria (PKU)Active, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2040Sponsor estimateNo phase registeredNCT06309979A Study to Assess Growth in Children With Idiopathic Short StatureBioMarin Pharmaceutical · Idiopathic Short StatureRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2026Sponsor estimatePhase 2NCT06382155A Phase 2 Study of Vosoritide in Children With Idiopathic Short StatureBioMarin Pharmaceutical · Idiopathic Short StatureRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 19, 2026Sponsor estimatePhase 1NCT06738017Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult ParticipantsBioMarin Pharmaceutical · Alpha 1-Antitrypsin DeficiencyActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2028Sponsor estimatePhase 2NCT07126262A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 MonthsBioMarin Pharmaceutical · HypochondroplasiaRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2033Sponsor estimateNo phase registeredNCT05813678A Long-term, Post-marketing Safety Study of Palynziq in Patients With PKU (PALace)BioMarin Pharmaceutical · Phenylketonuria (PKU)RecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2033Sponsor estimateNo phase registeredNCT06305234A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)BioMarin Pharmaceutical · Phenylketonuria (PKU)RecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 4, 2032Sponsor estimateNo phase registeredNCT05579548A Global, Multicenter Study to Assess Maternal, Fetal and Infant Outcomes of Exposure to Palynziq® (Pegvaliase) During Pregnancy and...BioMarin Pharmaceutical · Phenylketonuria, MaternalRecruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 16, 2025ActualPhase 3NCT06224907Phase 3 Study for Efficacy and Safety Outcomes Data in Japanese Patients With Severe Hemophilia ABioMarin Pharmaceutical · Hemophilia AActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT04554940A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With AchondroplasiaBioMarin Pharmaceutical · AchondroplasiaActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2038Sponsor estimatePhase 2NCT03989947An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical · AchondroplasiaActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2031Sponsor estimatePhase 3NCT03424018An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With AchondroplasiaBioMarin Pharmaceutical · AchondroplasiaActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2027Sponsor estimatePhase 2NCT02724228A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)BioMarin Pharmaceutical · AchondroplasiaActive, not recruitingBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2040Sponsor estimateNo phase registeredNCT05768386A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)BioMarin Pharmaceutical · Hemophilia AEnrolling by invitationBMRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 146 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner